Other · developed by Oruka Therapeutics
ORKA-001 is an agent given by subcutaneous injection and studied in plaque psoriasis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07449702 | Phase 2 | Plaque Psoriasis | Recruiting | ORKA |
| NCT07090330 | Phase 2 | Plaque Psoriasis | Active not recruiting | ORKA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Plaque Psoriasis
Updated Oct 25, 2026. Something wrong or missing? Report it on the ORKA page.
See ORKA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ORKA catalysts and pipeline →